MENU
+Compare
XENE
Stock ticker: NASDAQ
AS OF
Sep 23, 04:59 PM (EDT)
Price
$37.31
Change
-$0.04 (-0.11%)
Capitalization
2.88B

XENE Xenon Pharmaceuticals Forecast, Technical & Fundamental Analysis

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders... Show more

Industry: #Biotechnology
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XENE with price predictions
Sep 22, 2025

XENE's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for XENE moved out of overbought territory on September 03, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XENE as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XENE turned negative on September 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where XENE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

XENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 199 cases where XENE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.537) is normal, around the industry mean (19.858). P/E Ratio (0.000) is within average values for comparable stocks, (53.799). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.131). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (344.050).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

XENE is expected to report earnings to fall 207.48% to -114 cents per share on November 05

Xenon Pharmaceuticals XENE Stock Earnings Reports
Q3'25
Est.
$-1.15
Q2'25
Beat
by $2.06
Q1'25
Beat
by $0.08
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.01
The last earnings report on August 11 showed earnings per share of $1.07, beating the estimate of -99 cents. With 468.68K shares outstanding, the current market capitalization sits at 2.88B.
A.I. Advisor
published General Information

General Information

a provider of drug discovery and development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200-3650 Gilmore Way
Phone
+1 604 484-3300
Employees
259
Web
https://www.xenon-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VDSRX25.930.20
+0.78%
Victory Diversified Stock R6
SZCRX54.960.31
+0.57%
DWS Small Cap Core R6
CGIOX53.280.26
+0.49%
Calamos Growth and Income R6
RGBHX40.970.06
+0.14%
American Funds Global Balanced R5E
RIVCX13.40-0.02
-0.15%
Victory RS Investors C

XENE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+1.08%
IDYA - XENE
57%
Loosely correlated
+0.70%
CRNX - XENE
54%
Loosely correlated
-0.56%
IMVT - XENE
52%
Loosely correlated
+5.48%
NRIX - XENE
52%
Loosely correlated
-0.12%
ATXS - XENE
51%
Loosely correlated
+6.52%
More